Puma Biotechnology (PBYI) Total Debt (2011 - 2026)
Puma Biotechnology's (PBYI) quarterly Total Debt came in at $11.3 million in Q1 2026, down 79.84% YoY from $56.0 million in Q1 2025, and down 49.9% on a QoQ basis from $22.5 million in Q4 2025.
Puma Biotechnology (PBYI) Total Debt (2011 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 11 years of Total Debt data on file, last reported at $11.3 million in Q1 2026.
- Quarterly Total Debt fell 79.84% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (down 79.84% YoY) and the FY2025 annual result came in at $22.5 million, down 66.41% from the prior year.
- Total Debt retreated to $11.3 million in Q1 2026, from $22.5 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $100.0 million in Q1 2024 to a low of $11.3 million in Q1 2026.
- A 5-year average of $75.9 million and a median of $97.4 million in 2022 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2024 — Total Debt grew 1.42% — and 2026, when it plunged 79.84%.
- Tracing PBYI's Total Debt over 5 years: stood at $98.3 million in 2022, then rose by 1.37% to $99.7 million in 2023, then slumped by 32.72% to $67.0 million in 2024, then sank by 66.41% to $22.5 million in 2025, then tumbled by 49.9% to $11.3 million in 2026.
- The last three Total Debt figures came in at $11.3 million (Q1 2026), $22.5 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.28 Mn |
| Dec 31, 2025 | 22.52 Mn |
| Sep 30, 2025 | 33.72 Mn |
| Jun 30, 2025 | 44.87 Mn |
| Mar 31, 2025 | 55.98 Mn |
| Dec 31, 2024 | 67.05 Mn |
| Sep 30, 2024 | 78.08 Mn |
| Jun 30, 2024 | 89.06 Mn |
| Mar 31, 2024 | 100.02 Mn |
| Dec 31, 2023 | 99.66 Mn |
| Sep 30, 2023 | 99.30 Mn |
| Jun 30, 2023 | 98.95 Mn |
| Mar 31, 2023 | 98.62 Mn |
| Dec 31, 2022 | 98.31 Mn |
| Sep 30, 2022 | 97.99 Mn |
| Jun 30, 2022 | 97.68 Mn |
| Mar 31, 2022 | 97.38 Mn |
| Dec 31, 2021 | 97.09 Mn |
| Sep 30, 2021 | 96.80 Mn |
| Jun 30, 2021 | 100.14 Mn |